IBB - iShares Nasdaq Biotechnology ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
106.08
+0.56 (+0.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close105.52
Open105.48
Bid0.00 x 3200
Ask0.00 x 800
Day's Range105.30 - 106.41
52 Week Range89.01 - 122.97
Volume1,363,020
Avg. Volume2,578,135
Net Assets7.54B
NAV105.45
PE Ratio (TTM)9.79
Yield0.10%
YTD Return8.98%
Beta (3Y Monthly)1.45
Expense Ratio (net)0.47%
Inception Date2001-02-05
Trade prices are not sourced from all markets
  • MarketWatch17 hours ago

    Capicor Therapeutics' stock rockets on heavy volume after positive MD trial results

    Shares of Capricor Therapeutics Inc. nearly doubled (up 93%) in very active premarket trading Monday, after the biotechnology company announced upbeat results from a trial for its treatment (CAP-1002) of Duchenne muscular dystrophy. Trading volume was about 1.7 million shares ahead of the open, compared with the full-day average of about 56,500 shares. "I am incredibly pleased with the outcome of the interim analysis as it has demonstrated the biologic activity of CAP-1002 that has resulted in changes of clinically relevant outcomes including the upper limb, the hand and diaphragmatic function," said Craig McDonald, the principal investigator for the trial. The stock has lost 42.6% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has slipped 4.5% and the S&P 500 has gained 3.7%.

  • ETF Trends7 days ago

    Biotech ETFs Strengthen After Judge Blocks Trump’s Drug Pricing Rule

    Biotechnology stocks and sector-related exchange traded funds stood out on Tuesday after a U.S. District Court overruled President Donald Trump’s wishes to require drugmakers list prices on television ...

  • Drug Pricing War: Pharma, Biotech Stocks Score A Win Over Trump
    Investor's Business Daily7 days ago

    Drug Pricing War: Pharma, Biotech Stocks Score A Win Over Trump

    Late Monday, a U.S. District Court overturned President Trump's requirement that pharmaceutical companies and biotech stocks list the prices of their medicines in TV ads.

  • MarketWatch7 days ago

    Altimmune's stock soars after adding NASH candidate with purchase of Spitfire Pharma

    Shares of Altimmune Inc. soared 14% in premarket trading Tuesday, after the biopharmaceutical company announced a deal to buy Spitfire Pharma Inc., which is developing a treatment for non-alcoholic steatohepatitis, known as NASH. Altimmune will make an upfront payment of $5 million to Spitfire shareholders, who will also be eligible to receive an additional $8 million in regulatory and clinical milestones and up to $80 million in sales-based milestones. The deal is expected to close in July. Spitfire's NASH product candidate SP-1373 will be renamed ALT-801. "Compelling preclinical data generated by Spitfire suggests that ALT-801 could reverse obesity, a primary cause of NASH, thereby reducing excess liver fat, inflammation and fibrosis associated with the disease," said Altimmune Chief Executive Vipin Garg. Altimmune's stock has tumbled 21.1% over the past three months through Monday, while the iShares Nasdaq Biotechnology ETF has lost 4.3% and the S&P 500 has gained 3.4%.

  • MarketWatch11 days ago

    Tyme Technologies stock soars on heavy volume after upbeat update to cancer treatment study

    Shares of Tyme Technologies Inc. shot up 31% in active morning trading Friday, after the biotechnology company provided upbeat updated data from its phase 2 study of SM-88 for the treatment of pancreatic cancer. Trading volume swelled to 4.1 million shares, or already more than six-times the full-day average. The company said before the open that data from the study of SM-88 as an oral monotherapy showed that median overall survival of patients was 6.4 months, which compares favorably to historical trials which showed survival of 2.0 to 2.5 months. "We believe that these outcomes further justify advancing the development of SM-88," said Chief Medical Officer Giuseppe Del Priore. "We are increasingly encouraged that SM-88 has the potential to be a new treatment approach for late-stage pancreatic patients." Despite Friday's rally, the stock was still down 57% year to date, while the iShares Nasdaq Biotechnology ETF has gained 14% and the S&P 500 has advanced 19%.

  • MarketWatch13 days ago

    Unum Therapeutics stock plunges toward record low after FDA places 'clinical hold' on trial

    Shares of Unum Therapeutics Inc. tumbled 19% toward a record low in premarket trading Wednesday, after the Food and Drug Administration placed a "clinical hold" on the phase 1 trial of its cancer treatment ACTR087. The company said late Tuesday that the clinical hold was initiated after the biopharmaceutical company submitted a safety report regarding one patient in the trial experienced serious adverse events. Unum said it will work with the FDA to further review the events, and plans to report data from the trial at the end of the year. Analyst Peter Lawson at SunTrust Robinson Humphrey slashed his stock price target to $6 from $10, while keeping his rating at buy as the new target is more than triple current premarket prices. Lawson said that after speaking with management, he noted that the ACTR087 program was already de-prioritized in November. The stock has plunged 50% year to date through Tuesday, while the iShares Nasdaq Biotechnology ETF has gained 14% and the S&P 500 has advanced 19%.

  • MarketWatch14 days ago

    Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China

    Incyte Corp. said Tuesday it will receive an upfront payment of $17.5 million as part of a license agreement with Zai Lab Ltd. for the development and commercialization of Incyte's cancer treatment INCMGA0012 in China. Under terms of the agreement, Incyte is eligible to receive up to an additional $60 million in milestone payments, as well as tiered royalty payments from the "low to mid-twenties." In return, Zai Lab will have exclusive rights to commercialize INCMGA0012 in China, Hong Kong, Macau and Taiwan. Incyte and Zai Lab shares were still inactive in the premarket. Over the past three months, Incyte shares have lost 1.5% and Zai Lab's stock has climbed 19.4%, while the iShares Nasdaq Biotechnology ETF has slipped 2.7% and the S&P 500 has gained 3.4%.

  • MarketWatch20 days ago

    Adaptive Biotechnologies to sell more shares in IPO, as expected pricing increases

    Adaptive Biotechnologies Corp. increased the number of shares it will sell in its initial public offering, and the expecting pricing range increased as well, according to a filing with the Securities and Exchange Commission on Wednesday. The company is now offering 15 million shares, up from 12.5 million shares disclosed last week, while the expected pricing range is now $18 to $19 a share, up from $15 to $17 a share. The developer of immune-system derived disease treatments is now looking to raise $285 million, and be valued at up to $2.30 billion, before underwriters exercise any options to buy up to an additional 2.25 million shares. The upsized IPO comes at a time that the Renaissance IPO ETF has gained 2.0% over the past three months, the iShares Nasdaq Biotechnology ETF has slipped 2.9% and the S&P 500 has advanced 3.9%.

  • Despite Recent Volatility, Biotech Stocks Look Poised to Pop
    Investopedia21 days ago

    Despite Recent Volatility, Biotech Stocks Look Poised to Pop

    Recent news from a leading gene therapy company highlights the risks, but the charts suggest ample room to the upside for biotech stocks.

  • The Rush to Biotech ETFs Is Back On (IBB, XBI)
    Investopedia21 days ago

    The Rush to Biotech ETFs Is Back On (IBB, XBI)

    The often politically sensitive healthcare sector displayed that sensitivity in positive fashion Wednesday as a variety of exchange-traded funds (ETFs) tracking the sector surged on news that Senate Republicans are close to unveiling new healthcare legislation. On Wednesday, 15 ETFs hit all-time highs, and eight of those were healthcare funds.

  • MarketWatch25 days ago

    ContraVir's stock rockets off record low after 'positive feedback' on pre-IND for NASH

    Shares of ContraVir Pharmaceuticals Inc. rocketed 69% in active premarket trading Friday, to bounce off the previous session's record low close, after the biopharmaceutical company said it received "positive feedback" from the U.S. Food and Drug Administration in response to its pre-Investigational New Drug (pre-IND) meeting. Trading volume ballooned to over 760,000 shares, compared with the full-day average of about 1 million shares. The pre-IND meeting was with respect to the development of CRV431 for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH). The company said the feedback supports an IND submission for CRV431. "This IND submission for NASH will be in addition to our current existing IND for hepatitis B virus treatment," Chief Executive Robert Foster said. The stock has plunged 78% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 13% and the S&P 500 has advanced 18%.

  • MarketWatch29 days ago

    Adaptive Biotechnologies sets terms for IPO, to raise up to $212.5 million

    Adaptive Biotechnologies Corp. set terms for its initial public offering Monday, in which the developer of immune-system derived disease treatments is expected to raise up to $212.5 million and be valued at about $2.01 billion. The Seattle-based company is offering 12.5 million shares in the IPO, which is expected to price between $15 and $17 a share. If the underwriters, led by Goldman Sachs, J.P. Morgan and BofA Merrill Lynch, exercise all options to buy 1.875 million additional shares, the company could raise up to $244.4 million and be valued at up to $2.05 billion. The stock is expected to list on the Nasdaq under the ticker symbol "ADPT." The underwriters are led by Goldman Sachs, Citigroup and Wells Fargo Securities. After the IPO, the company will have about 118.5 million shares outstanding. The company recorded a net loss of $46.3 million on revenue of $55.7 million in 2018, after a loss of $42.5 million on $38.4 million in revenue in 2017. The company is looking to go public at a time that the iShares Nasdaq Biotechnology ETF has gained 10% year to date and the S&P 500 has advanced 15%.

  • MarketWatch29 days ago

    Karuna Therapeutics sets IPO terms, to be valued at up to $363 million

    Karuna Therapeutics Inc. set terms Monday for its initial public offering, in which the biopharmaceutical company developing treatments for neuropsychiatric conditions is expected to raise up to $74.4 million and be valued at about $363.3 million. The company is offering 4.375 million shares in the IPO, which is expected to price between $15 and $17 a share. The stock is expected to list on the Nasdaq under the ticker symbol "KRTX." The company said some existing shareholders and directors have expressed interest in buying up to a combined $30 million of shares at the IPO price. The underwriters are led by Goldman Sachs, Citigroup and Wells Fargo Securities. After the IPO, the company will have about 21.4 million shares outstanding. The company recorded a net loss of $17.5 million on no revenue in 2018, after a loss of $6.0 million on no revenue a year ago. The company is looking to go public at a time that the iShares Nasdaq Biotechnology ETF has lost 7.2% over the past three months, while the Renaissance IPO ETF has gained 3.2% and the S&P 500 has gained 2.5%.

  • MarketWatchlast month

    Morphic Holding sets terms of IPO to raise up to $80 million

    Morphic Holding Inc. set terms of its initial public offering, in which the Waltham, Mass.-based biopharmaceutical company focused on developing treatments for chronic diseases looks to raise up to $80 million. The company said it is offering 5 million shares, with the IPO expected to price between $14 and $16 a share, which would give Morphic an initial market capitalization of up to $457.5 million. The company expects the stock to list on the Nasdaq under the ticker symbol "MORF." The lead underwriters are Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities. Morphic recorded a net loss of $23.8 million on total collaboration revenue of $3.4 million in 2018, after a loss of $16.9 million on no revenue in 2017. The company is looking to go public at a time the Renaissance IPO ETF has edged up 2.3% over the past three months, the iShares Nasdaq Biotechnology ETF has lost 8.1% and the S&P 500 has gained 2.7%.

  • MarketWatchlast month

    Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal

    Shares of Kura Oncology Inc. soared 27% toward a record high in premarket trading Friday, after the biopharmaceutical company announced a phase 2 trial of its lymphoma treatment achieved its primary efficacy endpoint. The stock was on track to open above its March 2, 2018 record close of $23.40. The company said the results of the trial demonstrated "ongoing anti-tumor activity and a manageable safety profile" in advanced patients with angioimmunoblastic T-cell lymphoma (AITL), as well as non-AITL relapsed or refractory peripheral T-cell lymphoma (PTCL). "We believe these data support the potential to register tipifarnib in both the AITL and PTCL-NOS patient populations, and we look forward to seeking regulatory feedback on next steps for this program," said Chief Executive Troy Wilson. The stock has run up 32% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 8% and the S&P 500 has advanced 15%.

  • MarketWatchlast month

    Provention Bio's stock surges after calling off public stock offering

    Shares of Provention Bio Inc. surged 4.5% in premarket trade Thursday, after the biopharmaceutical company said it has terminated its planned public stock offering, citing current market conditions. The stock had more than tripled (up 217%) on Monday, after the company reported positive results from a study of its diabetes treatment. The stock then fell 13% on Tuesday, and 1.7% on Wednesday, after Provention looked to take advantage of the rally by proposing a public offering of 5.5 million common shares, which represented about 14.7% of the shares outstanding. On Thursday, the company said it decided not to sell shares after determining that "current market conditions are not conducive for an offering on terms that would be in the best interests of the company's shareholders." The stock has run up nearly 7-fold (up 569.5%) year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF has gained 7.2% and the S&P 500 has advanced 14.9%.

  • Barclays Has New Plays for Healthcare Fans
    SmarterAnalystlast month

    Barclays Has New Plays for Healthcare Fans

    Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays'  has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Can You Still Trust CannTrust (CTST) Stock? This Analyst Is No Longer Certain That You Can * Tesla (TSLA): Range Anxiety Is All Perception, but Still a Major Hurdle * Cannabis Stock HEXO to Benefit from Sector Chaos * Three Big Reveals as Jefferies Meets With Canopy Growth’s (CGC) New CFO

  • MarketWatchlast month

    Cancer genomics company Personalis expects to raise up to $107 million in IPO

    Personalis Inc. disclosed Friday terms of its initial public offering, in which the cancer genomics company could raise up to $106.7 million, and be valued at up to about $456 million. The company said it was offering 6,666,667 shares in the IPO, which is expected to price between $14 and $16 a share, and will have about 28.5 million shares outstanding after the offering. Personalis plans to use the IPO proceeds for the expansion of research and development, infrastructure, facilities, headcount, marketing spend and other capital expenditures. The stock is expected to list on the Nasdaq exchange under the ticker symbol "PSNL." The lead underwriters of the IPO are Morgan Stanley, BofA Merrill Lynch and Cowen. The company recorded a 2018 net loss of $19.9 million on revenue of $37.8 million, after a loss of $23.6 million on revenue of $9.4 million in 2017. Personalis is looking to go public at a time the iShares Nasdaq Biotechnology ETF has lost 6.4% over the past three months, while the both the Renaissance IPO ETF and the S&P 500 have gained 3.4%.

  • Biotech Sector Could Enter Bear Market
    Investopedialast month

    Biotech Sector Could Enter Bear Market

    Institutional players are abandoning biotech funds at a rapid pace, raising the odds that the sector will enter a bear market.

  • MarketWatch2 months ago

    Ideaya Biosciences' stock opened 40% above its IPO price, then pared most of its gains

    Shares of Ideaya Biosciences Inc. soared in its public debut, then pared most of its gains, biotechnology company focused on cancer treatments debuted as the broader stock market slumped. The first trade in Ideaya's stock was at $14.00 at 10:57 a.m. Eastern, 40% above the $10 initial public offering price. The stock was last 9.9% above the IPO price at $10.99. Meanwhile, the iShares Nasdaq Biotechnology ETF was down 1.3%, the Renaissance IPO ETF was shedding 2.3% and the S&P 500 was losing 1.7%. The company sold 5 million shares in the IPO to raise $50 million, as the IPO pricing implied a market capitalization of about $194.8 million. The company recorded a net loss of $34.3 million and no sales in 2018, compared with a 2017 loss of $11.9 million on no revenue.

  • MarketWatch2 months ago

    Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days

    Shares of Outlook Therapeutics Inc. rocketed on heavy volume in premarket trade Monday, putting them on track to nearly triple in three days, in the wake of the biotechnology company's upbeat update on a drug trial and bullish analyst report. The stock 27% ahead of the open on premarket leading volume of 4.2 million shares, after running up 37% on volume of 76.7 million shares on Friday and after soaring 68% on 51.7 million shares on Thursday. On Wednesday, the stock had closed at 91 cents. On Thursday, Oppenheimer analyst Leland Gershell started coverage of Outlook with an outperform rating and $12 stock price, and the company said two phase 3 studies remain on track with its plan to submit its monoclonal antibody therapeutic product for regulatory approval in 2020. The stock had still lost 78.1% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has lost 6.6% and the S&P 500 has gained 4.4%.

  • MarketWatch2 months ago

    Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days

    Shares of Outlook Therapeutics Inc. rocketed 38% in very active morning trade Friday, putting them on track to more than double in two days. Volume ballooned to 17.6 million shares, enough to make the stock the most actively traded on the Nasdaq exchange. The biotechnology company's stock had run up 68% on Thursday on trading volume of 51.7 million shares, after closing Wednesday at a record low of 91 cents, after Oppenheimer analyst Leland Gershell started coverage with an outperform rating and $12 stock price target. Outlook is investigating a formulation of a treatment of wet age-related macular degeneration. Outlook's stock was still down 47% year to date, while the iShares Nasdaq Biotechnology ETF has gained 7.9% and the S&P 500 has advanced 14%.

  • Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now
    SmarterAnalyst2 months ago

    Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now

    Get ready, bargain shoppers. Foamix (FOMX) has plummeted 27% since the beginning of the year and it looks like the stock received more lashes than it deserved -- at least, according to Wall Street analysts.2019 is poised to be a transformative year for Foamix. The company's acne treatment FMX101 is currently pending regulatory review in the U.S, and a PDUFA date of October 20, 2019 has been set. Furthermore, Foamix plans to submit a New Drug Application (NDA) for FMX103 during mid-2019, following positive long-term safety data in papulopustular rosacea patients. Now, let's take a closer look at what analysts are expecting ahead of October's FDA decision.FMX101's Approval Chances and ForecastsCredit Suisse analyst Vamil Divan sees a high likelihood of regulatory approval for FMX101, applying a 90% probability of success (POS). The analyst rates FOMX stock an Outperform with a $9.00 price target, which implies nearly 250% upside from current levels. With an FDA approval in hand (100% POS), Divan says his price target will be boosted to $11.00. According to the analyst, "an increase in the sample size (1,507 patients in this trial vs. ~500 each in the two prior trials) and improved site selection and training helped drive statistically significant [clinical] results," which put the company on track to win FDA approval.Similarly, H.C Wainright analyst Ram Selvaraju estimates the probability of regulatory approval at 85%, and assigns a $12.00 price target for the stock. If the price target is reached within 12 months, that would provide a 12-month return of nearly 360%. Selvaraju opined, "We believe that the current valuation situation presents an attractive entry point for value-focused investors, given the fact that Foamix currently trades about 2x book value [...] Our risk-adjusted net present value (rNPV) of FMX101 is $400M, which factors in an 85% probability of regulatory approval [...] We have employed a sum-of-the-parts valuation approach that yields a total projected firm value of $696M, which translates into a price objective of $12.00 assuming ~59M fully-diluted shares outstanding as of end-2019."Commercial Opportunity Selvaraju believes investors seem to be discounting both FMX101 and FMX103 from a commercial standpoint, but "this is unwarranted." Why? "These agents are based on well-known, validated and effective compounds in their respective target indications and have generated statistically significant efficacy data in large, robustlypowered pivotal studies. We also draw investors' attention to the large size and underserved nature of the target markets—namely, acne and rosacea—and the willingness of patients and physicians alike to try new formulations when they are introduced. Furthermore, we point to the user-friendly and well-tolerated nature of the Foamix formulations, which utilize the company's proprietary foam-based delivery technology to enhance efficacy while minimizing off-target systemic side effects," Selvaraju answers.Cowen analyst Ken Cacciatore has recently spoken with 3 dermatology KOLs; they all agreed that "the clinical data were as good or better than they would have expected," and, according to the analyst, one has indicated that "it looked "more impressive" than Aczone (which peaked at over $200MM+ before genericization)." Cacciatore believes that given the wide use of oral minocycline, clinicians are eager to have this option with potential similar efficacy yet without the the systemic side effects, and therefore, the marketing of FMX-101 should be a very easy story to tell. The analyst says "FMX-101 should be able to easily surpass the peak prescription levels of Aczone (via our consultants' feedback)," and "this would place FMX-101 to achieve at least $250MM in revenue." Furthermore, the analyst believes FMX-101 could ultimately reach his target of $350MM given what he believes will be "improved efficacy/outcomes." Cacciatore argues that "even undifferentiated dermatology assets are selling at 3x peak revenue. Using just FMX-101 alone – and the low-end ($250MM) of what we believe will be the ultimate product size – would yield a value of $750MM, or $13-15 per share."Bottom lineFoamix has seen its shares struggle mightily this year, but analysts continue to believe that this beaten-down biotech stock is a sure-fire winner. Analysts are confident that lead asset, FMX101, has substantial potential in treating acne, with an upcoming October 20, 2019 PDUFA date as a key potential positive catalyst for FOMX shares.This latest pullback has arguably skewed the risk-to-reward ratio for the better -- perhaps making FOMX an attractive buy for risk-tolerant investors. More recent articles from Smarter Analyst: * Should You Follow Jefferies and Buy CannTrust (CTST)? * Can this Cannabis Pharmaceutical Stock Sustain its Tremendous Momentum? * Qualcomm (QCOM) Faces Challenges, But the Stock Remains a 'Buy' * Aurora Cannabis (ACB): Investors Seem to Be Missing the Latin American Opportunity